|Bid||11.05 x 1300|
|Ask||13.90 x 900|
|Day's Range||11.69 - 12.00|
|52 Week Range||7.00 - 18.45|
|Beta (5Y Monthly)||1.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Nov 05, 2020|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||23.00|
BURNABY, British Columbia, Nov. 13, 2020 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical stage biopharmaceutical company, today announced that Dr. Simon Pimstone, Xenon's Chief Executive Officer, will participate in the following virtual investor conferences: * Guggenheim Healthcare 2nd Annual Neuro/Immunology Day on Monday, November 16, 2020 * Stifel 2020 Virtual Healthcare Conference on Tuesday, November 17, 2020 at 4:40 pm ET * Jefferies Virtual London Healthcare Conference on Thursday, November 19, 2020 at 9:40 am ET (2:40 pm GMT) The above listed dates and times are subject to change. Details on company presentations and webcasts can be found on the “Investors” section of Xenon's website at www.xenon-pharma.com. When available, webcasts will be posted for replay following the event for 30 days.About Xenon Pharmaceuticals Inc.We are a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.“Xenon” and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.Investor/Media Contact: Jodi Regts Xenon Pharmaceuticals Inc. Phone: 604.484.3353 Email: firstname.lastname@example.org
It's shaping up to be a tough period for Xenon Pharmaceuticals Inc. (NASDAQ:XENE), which a week ago released some...
Joining me on today's call are Dr. Simon Pimstone, Xenon's Chief Executive Officer; and Ian Mortimer, Xenon's President and Chief Financial Officer. Following this introduction, Simon will give an overview of Xenon's clinical programs, and then Ian will provide some high-level financial commentary.